{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:36Z","timestamp":1788998436024,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To investigate whether the evaluation of tumors, lymphoid cell-rich organs, and immune-related adverse events (IRAE) with <jats:sup>18<\/jats:sup>F-FDG PET\/CT can predict the efficacy and outcome of immunotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Forty patients who underwent <jats:sup>18<\/jats:sup>F-FDG-PET\/CT scans before and after therapy with immune checkpoint inhibitors from December 2013 to December 2016 were retrospectively enrolled (malignant melanoma, n = 21; malignant lymphoma, n = 11; renal cell carcinoma, n = 8). SUVmax of the baseline and first restaging scans were evaluated in tumors, spleen, bone marrow, thyroid and pituitary glands, and were correlated to best overall response in the first year after therapy; IRAE-affected areas were also evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Interval change between the baseline and first restaging scans showed that patients with a clinical benefit had a significant decrease in tumor parameters (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). All patients with an increase of SUVmax in the thyroid of more than 1.5 (n = 5) on the first restaging scan had a complete response (CR) in 1 year. Patients with CR within 1 year (n = 22) were significantly associated with a favorable long-term outcome (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002). Nine patients with IRAE findings had CR at final evaluation. Among IRAE, thyroiditis was seen significantly earlier than arthritis (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.040).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The decrease of tumor parameters at early time-point PET scans was seen in patients with immunotherapy who had clinical benefit within 1 year. PET-detectable IRAE was useful for prediction of a favorable outcome. Early development of thyroiditis may particularly represent an early response indicator to immunotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002453","type":"journal-article","created":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T22:41:29Z","timestamp":1549147289000},"page":"e272-e279","source":"Crossref","is-referenced-by-count":97,"title":["Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET\/CT"],"prefix":"10.1097","volume":"44","author":[{"given":"Tomomi","family":"Nobashi","sequence":"first","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Baratto","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil A.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Toriihara","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Hatami","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Yohannan","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Mittra","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","year":"2015","journal-title":"Science"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","year":"2016","journal-title":"JAMA Oncol"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","article-title":"Absolute number of new lesions on 18F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab","volume":"45","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2967\/jnumed.117.193011","article-title":"18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","year":"2016","journal-title":"Pituitary"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/thy.2016.0562","article-title":"Clinical features of nivolumab-induced thyroiditis: a case series study","volume":"27","year":"2017","journal-title":"Thyroid"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","year":"2011","journal-title":"Am J Roentgenol"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","year":"2017","journal-title":"Lancet Oncol"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","article-title":"Predictive value of early 18F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study","volume":"42","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2967\/jnumed.109.070946","article-title":"Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab","volume":"51","year":"2010","journal-title":"J Nucl Med"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","year":"2016","journal-title":"Clin Cancer Res"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00277-015-2311-5","article-title":"Diffuse thyroid 18F-FDG uptake after R-CHOP therapy predicts favorable outcome in patients with DLBCL","volume":"94","year":"2015","journal-title":"Ann Hematol"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/BF03350810","article-title":"Favorable predictive value of thyroid autoimmunity in high aggressive breast cancer","volume":"30","year":"2007","journal-title":"J Endocrinol Invest"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003072-201904000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T05:14:35Z","timestamp":1695618875000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201904000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002453","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}